Baicalein for Alzheimer's Disease
Also known as: 5,6,7-Trihydroxyflavone, Scutellaria baicalensis extract
Baicalein inhibits both amyloid-beta and tau aggregation while reducing 12/15-lipoxygenase-mediated neuroinflammation.
Mechanism of Action
Baicalein inhibits Aβ fibril formation, reduces tau aggregation, and suppresses 12/15-lipoxygenase (which produces pro-inflammatory lipid mediators in AD brain). It activates Nrf2 for antioxidant defense and modulates autophagy.
General mechanism: Flavone from Scutellaria. 12/15-LOX inhibitor, α-synuclein aggregation inhibitor, ferroptosis modulator, Nrf2 activator.
Current Evidence
Preclinical AD models show reduced pathology and improved cognition. 12/15-LOX inhibition is a validated AD target. No clinical trials.
Clinical Status: Preclinical. Traditional Chinese medicine use (Scutellaria baicalensis).
Safety Profile
Safe. Traditional medicine use. GI effects possible. May interact with iron metabolism at high doses.
Key Research Questions
- Does baicalein's 12/15-LOX inhibition reduce AD neuroinflammation uniquely?
- Can baicalein prevent protein aggregation in both AD and PD?